HUP0104943A3 - Controlled release formulation comprising gnrh-ii and its use - Google Patents
Controlled release formulation comprising gnrh-ii and its useInfo
- Publication number
- HUP0104943A3 HUP0104943A3 HU0104943A HUP0104943A HUP0104943A3 HU P0104943 A3 HUP0104943 A3 HU P0104943A3 HU 0104943 A HU0104943 A HU 0104943A HU P0104943 A HUP0104943 A HU P0104943A HU P0104943 A3 HUP0104943 A3 HU P0104943A3
- Authority
- HU
- Hungary
- Prior art keywords
- gnrh
- controlled release
- release formulation
- formulation
- controlled
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9826662A GB2344287A (en) | 1998-12-03 | 1998-12-03 | Controlled release pharmaceutical formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0104943A2 HUP0104943A2 (en) | 2002-06-29 |
| HUP0104943A3 true HUP0104943A3 (en) | 2002-08-28 |
Family
ID=10843631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0104943A HUP0104943A3 (en) | 1998-12-03 | 1999-12-02 | Controlled release formulation comprising gnrh-ii and its use |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1140133A1 (en) |
| JP (1) | JP2002531411A (en) |
| KR (1) | KR20010089538A (en) |
| CN (1) | CN1332635A (en) |
| AU (1) | AU770676B2 (en) |
| BR (1) | BR9915943A (en) |
| CA (1) | CA2353798A1 (en) |
| CZ (1) | CZ20011893A3 (en) |
| EE (1) | EE200100293A (en) |
| GB (1) | GB2344287A (en) |
| HR (1) | HRP20010421A2 (en) |
| HU (1) | HUP0104943A3 (en) |
| IL (1) | IL143496A0 (en) |
| MX (1) | MXPA01005543A (en) |
| NO (1) | NO20012636L (en) |
| NZ (1) | NZ511984A (en) |
| PL (1) | PL348575A1 (en) |
| RU (1) | RU2233170C2 (en) |
| SK (1) | SK7552001A3 (en) |
| TR (1) | TR200102273T2 (en) |
| WO (1) | WO2000032218A1 (en) |
| ZA (1) | ZA200104530B (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1909814B1 (en) | 2005-07-26 | 2015-06-24 | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) | Peptides for induction and enhancement of apoptosis in tumor cells |
| GB0616111D0 (en) | 2006-06-16 | 2006-09-20 | Ardana Bioscience Ltd | Agents, methods and uses |
| CN102448482A (en) | 2009-03-27 | 2012-05-09 | 范安德尔研究所 | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use |
| WO2011032099A1 (en) | 2009-09-11 | 2011-03-17 | The Board Of Trustees Of The University Of Illinois | Methods of treating diastolic dysfunction and related conditions |
| US20120208762A1 (en) | 2009-10-27 | 2012-08-16 | The Board Of Trustees Of The University Of Illinois | Methods of Diagnosing Diastolic Dysfunction |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| JP2013518115A (en) | 2010-01-27 | 2013-05-20 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
| EP2547359B1 (en) | 2010-03-15 | 2016-03-09 | The Board of Trustees of the University of Illionis | Inhibitors of beta integrin-g protein alpha subunit binding interactions |
| AU2011268327B2 (en) | 2010-06-16 | 2016-02-25 | Indiana University Research And Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
| US20120004182A1 (en) | 2010-07-02 | 2012-01-05 | Carsten Gruendker | Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells |
| WO2012087943A2 (en) | 2010-12-20 | 2012-06-28 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
| CN103458920B (en) | 2010-12-22 | 2016-07-06 | 印第安那大学科技研究公司 | Show the glucagon analogs of GIP receptor active |
| RS56173B1 (en) | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
| US9415123B2 (en) | 2011-10-10 | 2016-08-16 | The Regents Of The University Of Michigan | Polymeric nanoparticles for ultrasound imaging and therapy |
| RU2014117678A (en) | 2011-11-17 | 2015-12-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Glucagon superfamily peptides with glucocorticoid receptor activity |
| US9573987B2 (en) | 2011-12-20 | 2017-02-21 | Indiana University Research And Technology Corporation | CTP-based insulin analogs for treatment of diabetes |
| MX2014015205A (en) | 2012-06-14 | 2015-08-14 | Ambrx Inc | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides. |
| KR20150023013A (en) | 2012-06-21 | 2015-03-04 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Glucagon analogs exhibiting gip receptor activity |
| TWI644920B (en) | 2012-06-21 | 2018-12-21 | 美商印第安納大學科技研究公司 | Analogs of glucagon exhibiting gip receptor activity |
| EP3395358B1 (en) | 2012-09-26 | 2019-11-06 | Indiana University Research and Technology Corporation | Insulin analog dimers |
| US20160024169A1 (en) | 2013-03-14 | 2016-01-28 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
| WO2015120187A1 (en) | 2014-02-05 | 2015-08-13 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants |
| US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| JP6912386B2 (en) | 2015-01-26 | 2021-08-04 | ザ ユニバーシティー オブ シカゴ | CAR T cells that recognize cancer-specific IL13Rα2 |
| WO2016123142A1 (en) | 2015-01-26 | 2016-08-04 | The University Of Chicago | IL13RAα2 BINDING AGENTS AND USE THEREOF IN CANCER TREATMENT |
| CN104789524A (en) * | 2015-04-30 | 2015-07-22 | 四川大学 | Osteoporotic rat primary osteoblasts isolated culture method and application thereof |
| WO2017024111A1 (en) | 2015-08-04 | 2017-02-09 | The University Of Chicago | Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6 |
| CA3050811A1 (en) * | 2017-01-20 | 2018-07-26 | Immune System Regulation Holding Ab | Novel compounds (immunorhelins) |
| CA3068588A1 (en) | 2017-06-30 | 2019-01-03 | Amgen Inc. | Methods of treating heart failure with cardiac sarcomere activators |
| BR112020002013B1 (en) | 2017-08-03 | 2023-01-24 | Amgen Inc | IL-21 MUTEINS, METHOD OF PREPARATION, NUCLEIC ACID, VECTOR, HOST CELL, KIT, USE OF THEM AND PHARMACEUTICAL COMPOSITION |
| SG11202001499WA (en) | 2017-09-08 | 2020-03-30 | Amgen Inc | Inhibitors of kras g12c and methods of using the same |
| CA3076207A1 (en) | 2017-09-18 | 2019-03-21 | The Regents Of The University Of California | Claudin6 antibodies and methods of treating cancer |
| CA3087273A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Anti-pd-1 antibodies and methods of treatment |
| US20200085776A1 (en) | 2018-09-10 | 2020-03-19 | Cardax, Inc. | Methods of Reducing C-Reactive Protein and/or Treating Cardiovascular Disease |
| US20220162299A1 (en) | 2019-03-20 | 2022-05-26 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
| EP3785734B1 (en) * | 2019-03-26 | 2023-04-12 | Novel Pharma Inc. | Long-acting fatty acid-binding gnrh derivative and pharmaceutical composition comprising same |
| WO2020210376A1 (en) | 2019-04-09 | 2020-10-15 | The Board Of Trustees Of The University Of Illinois | Drug adsorbed highly porous activated carbon for enhanced drug delivery |
| US20230190725A1 (en) | 2019-04-29 | 2023-06-22 | The Board Of Trustees Of The University Of Illinois | Mek inhibitors for corneal scarring and neovascularization |
| EP3962945A1 (en) | 2019-04-30 | 2022-03-09 | Instituto de Medicina Molecular João Lobo Antunes | Rank pathway inhibitors in combination with cdk inhibitors |
| WO2020263793A1 (en) | 2019-06-24 | 2020-12-30 | Amgen Inc. | Inhibition of sirp-gamma for cancer treatment |
| AU2020340442A1 (en) | 2019-08-30 | 2022-03-03 | Research Institute At Nationwide Children's Hospital | Copper-ATSM for treating neurodegenerative disorders associated with mitochondrial dysfunction |
| TW202216778A (en) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit and cd112r blockade |
| EP4281187A1 (en) | 2021-01-20 | 2023-11-29 | Bioentre LLC | Ctla4-binding proteins and methods of treating cancer |
| WO2023137161A1 (en) | 2022-01-14 | 2023-07-20 | Amgen Inc. | Triple blockade of tigit, cd112r, and pd-l1 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH661206A5 (en) * | 1983-09-23 | 1987-07-15 | Debiopharm Sa | PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HORMONDEPENDENT DISEASES. |
| DE3414595A1 (en) * | 1984-04-18 | 1985-10-31 | Hoechst Ag, 6230 Frankfurt | USE OF GONADOLIBERIN AND GONADOLIBERINAGONISTS FOR TREATING CLIMATE COMPLAINTS |
| US4540513A (en) * | 1984-09-25 | 1985-09-10 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Decapeptide having gonadotropin releasing activity |
| US4721775A (en) * | 1985-08-26 | 1988-01-26 | Board Of Regents, The University Of Texas System | Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids |
| ZA918168B (en) * | 1990-10-16 | 1993-04-14 | Takeda Chemical Industries Ltd | Prolonged release preparation and polymers thereof. |
| IT1243390B (en) * | 1990-11-22 | 1994-06-10 | Vectorpharma Int | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION. |
| CA2192773C (en) * | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Production of sustained-release preparation for injection |
| WO1997047743A1 (en) * | 1996-06-13 | 1997-12-18 | Zymogenetics, Inc. | Human type ii gonadotropin-releasing hormone receptor |
-
1998
- 1998-12-03 GB GB9826662A patent/GB2344287A/en not_active Withdrawn
-
1999
- 1999-12-02 TR TR2001/02273T patent/TR200102273T2/en unknown
- 1999-12-02 CZ CZ20011893A patent/CZ20011893A3/en unknown
- 1999-12-02 JP JP2000584909A patent/JP2002531411A/en active Pending
- 1999-12-02 IL IL14349699A patent/IL143496A0/en unknown
- 1999-12-02 BR BR9915943-0A patent/BR9915943A/en not_active IP Right Cessation
- 1999-12-02 RU RU2001118040/15A patent/RU2233170C2/en not_active IP Right Cessation
- 1999-12-02 CA CA002353798A patent/CA2353798A1/en not_active Abandoned
- 1999-12-02 AU AU15732/00A patent/AU770676B2/en not_active Ceased
- 1999-12-02 NZ NZ511984A patent/NZ511984A/en unknown
- 1999-12-02 PL PL99348575A patent/PL348575A1/en not_active Application Discontinuation
- 1999-12-02 EP EP99958357A patent/EP1140133A1/en not_active Withdrawn
- 1999-12-02 MX MXPA01005543A patent/MXPA01005543A/en unknown
- 1999-12-02 WO PCT/GB1999/004045 patent/WO2000032218A1/en not_active Application Discontinuation
- 1999-12-02 SK SK755-2001A patent/SK7552001A3/en unknown
- 1999-12-02 CN CN99815183A patent/CN1332635A/en active Pending
- 1999-12-02 HU HU0104943A patent/HUP0104943A3/en unknown
- 1999-12-02 EE EEP200100293A patent/EE200100293A/en unknown
- 1999-12-02 KR KR1020017006883A patent/KR20010089538A/en not_active Application Discontinuation
-
2001
- 2001-05-29 NO NO20012636A patent/NO20012636L/en not_active Application Discontinuation
- 2001-06-01 HR HR20010421A patent/HRP20010421A2/en not_active Application Discontinuation
- 2001-06-01 ZA ZA200104530A patent/ZA200104530B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EE200100293A (en) | 2002-08-15 |
| CZ20011893A3 (en) | 2002-05-15 |
| NO20012636L (en) | 2001-07-12 |
| NO20012636D0 (en) | 2001-05-29 |
| GB9826662D0 (en) | 1999-01-27 |
| AU1573200A (en) | 2000-06-19 |
| HRP20010421A2 (en) | 2002-06-30 |
| HUP0104943A2 (en) | 2002-06-29 |
| KR20010089538A (en) | 2001-10-06 |
| ZA200104530B (en) | 2002-06-04 |
| AU770676B2 (en) | 2004-02-26 |
| IL143496A0 (en) | 2002-04-21 |
| EP1140133A1 (en) | 2001-10-10 |
| CA2353798A1 (en) | 2000-06-08 |
| WO2000032218A1 (en) | 2000-06-08 |
| BR9915943A (en) | 2001-08-21 |
| GB2344287A (en) | 2000-06-07 |
| RU2233170C2 (en) | 2004-07-27 |
| SK7552001A3 (en) | 2002-02-05 |
| TR200102273T2 (en) | 2001-12-21 |
| JP2002531411A (en) | 2002-09-24 |
| CN1332635A (en) | 2002-01-23 |
| NZ511984A (en) | 2002-11-26 |
| MXPA01005543A (en) | 2003-07-14 |
| PL348575A1 (en) | 2002-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0104943A3 (en) | Controlled release formulation comprising gnrh-ii and its use | |
| EG24198A (en) | Extended release formulation | |
| HUP0103267A2 (en) | Glyphosate formulation and use thereof | |
| HRP20060251B1 (en) | Substituted oxasolidinones and their use | |
| HUP0104270A3 (en) | Herbicidal composition and use thereof | |
| HK1042084B (en) | Substituted benzimidazoles and their preparation and use | |
| AU4161899A (en) | Radiotherapeutical device and use thereof | |
| ZA982478B (en) | Compounds their use and preparation | |
| GB9813271D0 (en) | Composition and use | |
| GB0101035D0 (en) | Formulation and use thereof | |
| IL135457A0 (en) | Extended release formulation | |
| HUP0103636A3 (en) | 2-methyl-thieno-benzodiazepine formulation and its use | |
| HUP0203896A3 (en) | Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof | |
| HUP0103845A3 (en) | Disinfecting composition and its use | |
| IL145715A0 (en) | Formulation arrays and use thereof | |
| HUP0003840A3 (en) | Controlled released medical formulation | |
| HUP0103473A3 (en) | Phosphoglycolipid and methods for its use | |
| GB9811168D0 (en) | Direct hair-colouring compositions and the use thereof | |
| EG22491A (en) | Rest-breaking composition and use thereof | |
| PL345017A1 (en) | Coatings agent and the use thereof | |
| HUP0104723A3 (en) | New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use | |
| ZA9711047B (en) | Formulation and use. | |
| AU3432900A (en) | Colouring agent and the use thereof | |
| GB9911606D0 (en) | Composition and use | |
| GB9929581D0 (en) | Comjpositions and their use |